Form 4: Helius Medical Technologies CFO Receives Stock Options
SEC Form 4 Filing
Jeffrey S. Mathiesen, CFO and Treasurer of Helius Medical Technologies, received stock options for 404,000 shares under the company's 2022 Equity Incentive Plan.
Summary
- Jeffrey S. Mathiesen, the CFO and Treasurer of Helius Medical Technologies, received a grant of stock options.
- The options are for 404,000 shares of Class A Common Stock.
- The exercise price of the options is $0.965 per share.
- The options were granted on July 2, 2024, and expire on July 1, 2034.
- 62.5% of the options vested immediately, with the remainder vesting in equal quarterly installments over the next ten quarters, starting September 30, 2024, contingent upon continued service.
Sentiment
Score: 7
Explanation: The document indicates a standard executive compensation practice, suggesting stability and alignment of interests. It's a neutral to slightly positive event.
Positives
- The grant of stock options aligns the CFO's interests with those of the shareholders.
- The vesting schedule incentivizes continued service and commitment from the CFO.
Industry Context
Stock option grants are a common form of executive compensation in the biotechnology industry, used to attract and retain talent and align management's interests with those of shareholders.
Comparison to Industry Standards
- Stock option grants are a standard component of executive compensation packages in the biotech industry.
- Companies like Inovio Pharmaceuticals and Novavax also utilize stock options as part of their executive compensation plans.
- The vesting schedule and exercise price are typical for such grants, designed to incentivize long-term performance.
Stakeholder Impact
- Shareholders may view the stock option grant as a positive incentive for the CFO to drive company performance.
- Employees may see this as a sign of the company's commitment to its leadership team.
Key Dates
| Date | Description |
|---|---|
| 07/02/2024 | Date of stock option grant |
| 09/30/2024 | Start date for quarterly vesting of remaining options |
| 07/01/2034 | Expiration date of the stock options |
Keywords
stock options, Helius Medical Technologies, CFO, Jeffrey S. Mathiesen, equity incentive plan, Form 4, executive compensation
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.